Martin Shkreli on AI, Pharma, and What Actually Matters

2026-04-23 · Source: The a16z Show · Field: Business & Management — Corporate Strategy & Leadership, Entrepreneurship & Start-ups · Depth: Intermediate, extended

Summary

Martin Shkreli, an American investor and businessman, offers his perspective on the AI landscape, future computing, and the pharma industry. He highlights a shift in AI from intelligence benchmarks to economic value capture, noting that compute is becoming more expensive. Shkreli is bullish on photonic computing, which he believes could offer 1000x to 1 million X performance improvements over current silicon, representing a potential \$5-10 trillion market. He criticizes "vibe coding" in software, emphasizing the need for deep expertise in complex fields like finance and biotech. In pharma, he expresses strong skepticism about unregulated peptides, advocating instead for focusing on rare diseases and severe cancers, where significant value and impact can be found despite the arduous drug development process. He also touches on the long-term challenges of patent expiration for blockbuster drugs like GLP-1s.

Key takeaway

For entrepreneurs and investors navigating the evolving tech landscape, prioritize fundamental hardware innovation like photonic computing, which promises 1000x performance gains and a \$5-10 trillion market. Avoid short-term "vibe coding" fads and instead cultivate deep industry expertise, especially in complex sectors like pharma, where real-world validation and addressing critical unmet needs drive sustainable value. Be prepared for 10-20 year investment horizons, as incumbents resist self-disruption and long-term plays yield significant returns.

Key insights

Value capture in AI is shifting from intelligence to economics, necessitating fundamental hardware innovation beyond silicon.

Principles

• Deep expertise and real-world validation are critical in complex industries.
• Disruptive hardware requires patient, long-term investment horizons.
• Drug development success targets severe, unmet medical needs.

Method

Achieve 1000x-1M X performance in optical computing by staying entirely within optics, avoiding electric-to-optical conversions, and solving non-linearity and memory challenges.

In practice

• Invest in photonic computing startups for next-gen hardware.
• Focus drug development on rare diseases and severe cancers.
• Beware of "vibe coding" for critical, high-stakes software.

Topics

• AI Ecosystem
• Photonic Computing
• Hardware Innovation
• Drug Development
• Pharma Industry
• Venture Capital Strategy
• Market Dynamics

Best for: Investor, Entrepreneur, Executive

Related on AIssential

• AI Is Forging A New RevOps Identity — AI fundamentally shifts RevOps identity from technical mastery to judgment, trust, and decision governance.
• Intelligence Per Dollar — AI model evaluation is shifting from raw performance to cost-efficiency, prioritizing "intelligence per dollar."
• AI is becoming the opium of the people. — AI's emerging business model centers on cultivating user dependency to enable subscription-based "rental" of cognitive abilities.
• MLWhiz Weekly Recsys/ML/GenAI Newsletter # 9 - The week AI started its IPOs — The AI industry is rapidly maturing, transitioning to public markets while new models and research advance core capabilities.
• Another 1263635 startup’s destroyed! — The headline "Another 1263635 startup's destroyed!" suggests AI's disruptive power is causing widespread startup failures.
• Hybrid Squads Model for Enterprise Product Teams — Balance enterprise stability with execution agility by separating team ownership from temporary project-based capacity allocation.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The a16z Show.